Loss of cyclin-dependent kinase inhibitor p27(Kip1) is a novel prognostic factor in localized human prostate adenocarcinoma

John Tsihlias, Linda R. Kapusta, Gerrit DeBoer, Izabella Morava-Protzner, Ingrid Zbieranowski, Nandita Bhattacharya, G. Charles Catzavelos, Laurence H. Klotz, Joyce M. Slingerland

Research output: Contribution to journalArticle

303 Scopus citations

Abstract

p27(Kip1) is a cyclin-dependent kinase inhibitor that negatively regulates cell proliferation by mediating cell cycle arrest in G1. This study was undertaken to assess the prognostic value of p27(Kip1) in localized human prostate cancer. Archival material from 113 radical prostatectomy specimens obtained between 1985 and 1993 was stained immunohistochemically for p27(Kip1) protein using a commercially available antibody. Patient charts were reviewed for preoperative serum prostate-specific antigen, clinical and pathological staging, Gleason tumor grade, time to biochemical and clinical recurrence, and survival. Strong p27(Kip1) staining was uniformly seen in benign prostatic epithelial components in all tumor sections. p27(Kip1) staining was reduced in most prostate cancers and was variable in prostatic intraepithelial neoplasia. Decreased p27(Kip1) staining (<25% of nuclei stained positive for p27(Kip1) correlated with seminal vesicle involvement (P = 0.0032) and with higher Gleason grade (P = 0.0114). On univariate analysis, low p27(Kip1) predicted an increased risk of treatment failure in the node- negative cohort (P = 0.0037) and in the subset who did not receive neoadjuvant hormonal therapy (P = 0.049). Low p27(Kip1) expression was an independent predictor of treatment failure on multivariate analysis of lymph node negative prostate cancers following radical retropubic prostatectomy (n = 102; P = 0.047). Seminal vesicle involvement (P = 0.034) and positive surgical margins (P = 0.047) were also independent prognostic factors for disease recurrence. In patients who received preoperative neoadjuvant hormonal therapy, low p27(Kip1) in the pathological specimen was an even stronger predictor of outcome than it was in the entire group (n = 23, P = 0.015).

Original languageEnglish (US)
Pages (from-to)542-548
Number of pages7
JournalCancer Research
Volume58
Issue number3
StatePublished - Feb 1 1998
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Loss of cyclin-dependent kinase inhibitor p27(Kip1) is a novel prognostic factor in localized human prostate adenocarcinoma'. Together they form a unique fingerprint.

  • Cite this

    Tsihlias, J., Kapusta, L. R., DeBoer, G., Morava-Protzner, I., Zbieranowski, I., Bhattacharya, N., Catzavelos, G. C., Klotz, L. H., & Slingerland, J. M. (1998). Loss of cyclin-dependent kinase inhibitor p27(Kip1) is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Research, 58(3), 542-548.